NASDAQ: INTS
Intensity Therapeutics Inc Stock Ownership - Who owns Intensity Therapeutics?

Insider buying vs selling

Have Intensity Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Joseph TalamoChief Financial Officer2025-06-3014,179$0.26
$3.70kBuy
John M. WesolowskiPrincipal Accounting Officer2025-06-3069,745$0.26
$18.20kBuy

1 of 1

INTS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when INTS insiders and whales buy or sell their stock.

INTS Shareholders

What type of owners hold Intensity Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Lewis H. Bender4.25%2,000,000$1.46MInsider
Sapient Capital LLC2.08%976,797$713.06kInstitution
Sentinus LLC0.42%199,316$145.50kInstitution
Brown Advisory Inc0.28%130,072$94.95kInstitution
Mesirow Financial Investment Management Inc0.23%110,000$80.30kInstitution
John M. Wesolowski0.16%76,436$55.80kInsider
Geode Capital Management LLC0.15%72,813$53.15kInstitution
Sigma Planning Corp0.15%69,167$50.49kInstitution
Warberg Asset Management LLC0.15%68,400$49.93kInstitution
Jane Street Group LLC0.10%44,897$32.77kInstitution

1 of 3

INTS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
INTS4.20%4.44%Net Buying
QTTB30.40%69.60%Net SellingNet Selling
VRCA33.62%66.38%Net Selling
BCAB27.10%35.36%Net SellingNet Selling
SONN2.67%68.64%

Intensity Therapeutics Stock Ownership FAQ

Who owns Intensity Therapeutics?

Intensity Therapeutics (NASDAQ: INTS) is owned by 4.20% institutional shareholders, 4.44% Intensity Therapeutics insiders, and 91.35% retail investors. Lewis H. Bender is the largest individual Intensity Therapeutics shareholder, owning 2.00M shares representing 4.25% of the company. Lewis H. Bender's Intensity Therapeutics shares are currently valued at $1.46M.

If you're new to stock investing, here's how to buy Intensity Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.